MA28639B1 - Vaccins - Google Patents

Vaccins

Info

Publication number
MA28639B1
MA28639B1 MA29494A MA29494A MA28639B1 MA 28639 B1 MA28639 B1 MA 28639B1 MA 29494 A MA29494 A MA 29494A MA 29494 A MA29494 A MA 29494A MA 28639 B1 MA28639 B1 MA 28639B1
Authority
MA
Morocco
Prior art keywords
vaccines
Prior art date
Application number
MA29494A
Other languages
English (en)
Inventor
Claudine Elvire Marie Bruck
Vincent Brichard
Remi M Palmantier
Melinda Meaders
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA28639B1 publication Critical patent/MA28639B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA29494A 2004-05-04 2006-11-28 Vaccins MA28639B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0409940.4A GB0409940D0 (en) 2004-05-04 2004-05-04 Vaccine

Publications (1)

Publication Number Publication Date
MA28639B1 true MA28639B1 (fr) 2007-06-01

Family

ID=32482653

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29494A MA28639B1 (fr) 2004-05-04 2006-11-28 Vaccins

Country Status (16)

Country Link
US (1) US20070243196A1 (fr)
EP (1) EP1755657A2 (fr)
JP (1) JP2007536326A (fr)
CN (1) CN1980691A (fr)
AU (1) AU2005237256A1 (fr)
BR (1) BRPI0510570A (fr)
CA (1) CA2564470A1 (fr)
GB (1) GB0409940D0 (fr)
IL (1) IL178681A0 (fr)
MA (1) MA28639B1 (fr)
MX (1) MXPA06012723A (fr)
NO (1) NO20065480L (fr)
NZ (1) NZ550967A (fr)
RU (1) RU2006138283A (fr)
WO (1) WO2005105139A2 (fr)
ZA (1) ZA200608693B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007137986A2 (fr) * 2006-05-26 2007-12-06 Glaxosmithkline Biologicals Sa Méthode
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
EP2118128B1 (fr) * 2007-01-15 2012-11-07 GlaxoSmithKline Biologicals SA Protéine hybride comprenant les antigènes ny-eso-1 et lage-1
EP2125888B1 (fr) 2007-03-13 2015-12-02 University of Zurich Procédé pour obtenir des anticorps humains spécifiques d'une tumeur
AR066676A1 (es) 2007-05-24 2009-09-02 Glaxosmithkline Biolog Sa Composicion antigenica liofilizada que contiene un agonista del receptor tipo toll
WO2009127666A2 (fr) * 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Procédé et compositions
CN101381402B (zh) * 2008-10-20 2011-06-01 中国人民解放军第三军医大学 Ny-eso-1肿瘤抗原模拟表位及其应用
US20120039993A1 (en) 2009-03-17 2012-02-16 Glaxosmithkline Biologicals Sa Detection of Gene Expression
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
ES2617983T3 (es) * 2011-01-10 2017-06-20 Ct Atlantic Ltd. Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
PL3542819T3 (pl) * 2013-05-14 2022-01-10 Zoetis Services Llc Nowe kompozycje szczepionek zawierających oligonukleotydy immunostymulujące
JP6697384B2 (ja) 2013-07-25 2020-05-20 イグジキュア, インコーポレーテッドExicure, Inc. 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物
ES2725948T3 (es) 2014-06-04 2019-09-30 Exicure Inc Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
WO2016019298A2 (fr) * 2014-08-01 2016-02-04 Texas Tech University System Protéine de sperme 17 antigène testiculaire du cancer utilisée en tant que cible pour l'immunothérapie et le diagnostic du cancer du sein
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2018039629A2 (fr) 2016-08-25 2018-03-01 Northwestern University Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018226931A1 (fr) * 2017-06-07 2018-12-13 David Weiner Vaccins mage-a et méthodes de traitement les utilisant
WO2019061297A1 (fr) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 Peptide de fusion d'épitope de lymphocyte t auxiliaire cd4 et vaccin associé
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
EP0882246A1 (fr) * 1996-02-23 1998-12-09 BRITISH TELECOMMUNICATIONS public limited company Interconnexion optique
DE69943359D1 (de) * 1998-02-05 2011-05-26 Glaxosmithkline Biolog Sa Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens

Also Published As

Publication number Publication date
IL178681A0 (en) 2007-02-11
JP2007536326A (ja) 2007-12-13
GB0409940D0 (en) 2004-06-09
NZ550967A (en) 2009-01-31
CA2564470A1 (fr) 2005-11-10
BRPI0510570A (pt) 2007-11-20
MXPA06012723A (es) 2007-02-14
EP1755657A2 (fr) 2007-02-28
US20070243196A1 (en) 2007-10-18
AU2005237256A1 (en) 2005-11-10
NO20065480L (no) 2006-11-28
ZA200608693B (en) 2010-01-27
WO2005105139A3 (fr) 2006-04-13
WO2005105139A2 (fr) 2005-11-10
RU2006138283A (ru) 2008-06-10
CN1980691A (zh) 2007-06-13

Similar Documents

Publication Publication Date Title
MA28609B1 (fr) Vaccins
MA28639B1 (fr) Vaccins
MA28885B1 (fr) vaccins
DK1959991T3 (da) Terapeutisk vaccine
TWI365191B (en) Vaccine
DK1968631T3 (da) Vaccine
GB2434367B (en) Improved vaccines
ATE462445T1 (de) Prrs-impfstoffe
GB0504436D0 (en) Vaccine
ATE450271T1 (de) Impfstoff
BRPI0607474A2 (pt) vacinação enriquecida com glicosido-alquila
IS2922B (is) Bóluefni
GB0411150D0 (en) Vaccine
GB0413510D0 (en) Vaccine
GB0428381D0 (en) Vaccine
GB0412407D0 (en) Vaccine
AP2709A (en) An anti-theileriosis vaccine
GB0419918D0 (en) Vaccine
GB0406598D0 (en) Vaccine
GB0413371D0 (en) Vaccine
GB0416833D0 (en) Vaccine
GB0416398D0 (en) Vaccine
GB0413513D0 (en) Vaccine
GB0425339D0 (en) Vaccine
GB0412547D0 (en) Vaccine